rebel Financial rebel Financial
← All Posts
CRNX

Crinetics Pharmaceuticals, Inc.

August 29, 2026 • Author: Phil Ratcliff • CRNX
Item Proposal Vote
1 To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated as of July 6, 2026 (as it may amended from time to time, the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation ("Crinetics"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Vertex"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Vertex ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into Crinetics (the "Merger"), with Crinetics surviving the Merger as a wholly owned subsidiary of Vertex (the "Merger Proposal"). ✓ For
2 To consider and vote on the proposal to approve, by non-binding, advisory vote, compensation that will or may be paid or become payable to Crinetics' named executive officers that is based on or otherwise relates to the Merger and/or the other transactions contemplated by the Merger Agreement. ✓ For
3 To consider and vote on any proposal to adjourn the Special Meeting to a later date, if necessary or appropriate, to solicit additional votes if there are not sufficient votes to approve the Merger Proposal at the time of the Special Meeting. ✓ For
Attachments
📄
CRNX_Proxy_Statement_08242026.pdf 1.4 MB
📄
CRNX_Special_Proxy_Statement_08242026.pdf 1.8 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.